We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cancer Cells Persuaded to Self-Destruct

By Biotechdaily staff writers
Posted on 05 Sep 2002
A method has been developed to destroy cancer cells without damage to surrounding normal tissue through activation of double-stranded RNA (dsRNA)–dependent protein kinase (PKR), a potent growth inhibitory protein that is primarily activated in virally infected cells. More...
The method was described August 19, 2002, in the online edition of Nature Biotechnology.

PKR is activated as a result of viral invasion of normal cells. The activated protein triggers a process that results in death of the cell. Researchers at the Hebrew University of Jerusalem (Israel) developed a technique for inducing cancer cells that express mutated genes containing deletions or chromosomal translocations to activate PKR without activating it in normal cells. They found that antisense (AS) RNA complementary to fragments flanking the deletion or translocation could produce a dsRNA molecule of sufficient length (39-nucleotides) to activate PKR and induce cell death following hybridization with mutated but not wild-type mRNA.

This in vitro study was followed by experiments in mice with brain tumors. A lentiviral vector expressing the 39-nt AS sequence was found to strongly inhibit glioblastoma growth in mouse brain when injected after tumor cell implantation.

Professor Alex Levitzki of the department of biological chemistry of the Hebrew University cautioned that a great deal of laboratory and clinical work remains to be done before this technique will be able to be implemented in treatment of cancer patients.




Related Links:
Hebrew University of Jerusalem

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.